CURRENT PRACTICE OF RCT-BASED MODELLING CAN LEAD TO WRONG RESEARCH PRIORITIES

Published Dec 15, 2014
Rotterdam, The Netherlands – The current practice of prioritizing research in the context of conditional reimbursement can lead to wrong decisions since it relies on randomized controlled trials (RCT) based cost-effectiveness models, which do not reflect all uncertainties that are crucial in daily clinical practice. Treatment persistence, compliance, and broadening of indication can add substantial extra uncertainty to decisions about reimbursing treatments, according to a new study by the Institute for Medical Technology Assessment (iMTA) of Erasmus University Rotterdam. These uncertainties should be included in valuation-of-information analyses that are conducted to prioritize additional research, but usually they are not, as they are hardly relevant in RCTs. The additional ‘daily practice parameters’ do not merely add uncertainty, individually; they also interact with the RCT-based uncertainties, which may increase their impact. “Based on our experience with conditional reimbursement dossiers we know that decision-analytic models included in those dossiers do not properly represent daily practice. Thus, if the need for additional research is assessed at the beginning of the period of conditional reimbursement and this assessment is based solely on the RCT-based model, decisions can be very wrong.” said author Isaac Corro Ramos, PhD. Under the Dutch conditional reimbursement scheme, expensive new treatments can be accepted for reimbursement, provided that additional data is collected over a 4-year period in order to reduce uncertainty about the cost-effectiveness. Value-of-information analysis can be performed to decide which data is most relevant for increasing confidence in a correct reimbursement decision. The full study, “Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis,” is published in Value in Health

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×